AMBAR, an innovative treatment approach for Alzheimer's disease (AD) based on the combination of regular Plasmapheresis with albumin and immunoglobulin infusions under development in phase IIb/III, may offer a new treatment pathway for the illness in the future.
Primary outcomes of AMBAR trial have demonstrated a significant reduction in the progression of Alzheimer's in moderate patients.
The latest results complement and confirm these primary outcomes, not only for patients with moderate-phase Alzheimer's disease, but also for patients in the mild phase of the disease.
"Grifols will continue to explore the potential of plasma proteins and plasma exchange in further studies."
Víctor Grífols, Grifols Chairman
"The results are very encouraging and confirm our line of research."
Antonio Páez, M.D., Grifols Medical Director and Head of the AMBAR Clinical Program
"This is the most significant development in the treatment of Alzheimer's disease I've seen in over 15 years. The results are extremely promising."
Mercè Boada, M.D., Ph.D., Director of Fundació ACE.
"Those findings open new avenues for the research of neurodegenerative disorders that have the potential to offer a new modality of treatment."
Dr. Óscar López, Director of the AD Research Center of the University of Pittsburgh
AMBAR in the media:
It is currently estimated that 35 million people worldwide suffer from Alzheimer's, and this figure is continuing to grow.
Grifols and Alzheimer's
Since 2004, we have led a broad range of research initiatives on Alzheimer's.
The AMBAR hypothesis
AMBAR is an innovative treatment proposal aimed at slowing the progression of Alzheimer's disease through periodic plasma exchange.
AMBAR is an international and multicenter clinical trial designed by Grifols in collaboration with Fundació ACE in Barcelona, Spain; and the Alzheimer Disease Research Center in Pittsburgh, PA, U.S.